1. Home
  2. News
  3. GW Pharma Denied Blanket Patent on Treating Epilepsy with Cannabinoids

Cannabis Education Cannabis Laws Cannabis News Cannabis Safety Cannabis Technology CBD CBD Laws CBD News Hemp CBD Hemp Laws Hemp News Medical Marijuana

GW Pharma Denied Blanket Patent on Treating Epilepsy with Cannabinoids

By Beard Bros. Crew
GW Pharma Denied Blanket Patent on Treating Epilepsy with Cannabinoids

Contribute your opinion or news articles to Beard Bros Media

Create content

Small victories are still victories

When UK-based GW Pharmaceuticals successfully convinced the FDA and the DEA to allow them to bring their cannabis-derived CBD isolate tincture to the U.S. market last year, surely some bottles got popped at the GW HQ as their anti-seizure medication, Epidiolex, stood unimpeded on a path to piles of cash.

When the federal government somehow got organized enough to pass the 2018 Farm Bill in December of last year, GW Pharma likely breathed a sigh of relief and chugged a bit more bubbly once their buds at the FDA clarified that even though the hemp plant is no longer illegal, many products utilizing hemp-derived CBD still would be.

So, yes, we celebrate small victories when we can, and last week we got one from the U.S. patent Office.

U.S. Patent #9066920B2 has been in the works since 2010, but on January 3rd of this year, the application was officially, and in no uncertain terms, denied.



Here’s what they were asking to patent, look for the key words right at the beginning of this abstract:

This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

Ok so generally speaking, it appears that GW Pharma was looking to put a patent on treating epilepsy with CBD and/or THCV. But did you find the real razor in the apple above?

The dangerously ambiguous term “use of one or more cannabinoids…” intentionally leaves too much legal wiggle room for them to potentially weaponize that patent to discourage competition.

Epidiolex is said to come with a $32,000+ price tag for a one year treatment, so stifling competition helps their bottom line.

If Epidiolex is safe and helps even one child – and there are success stories – then GW Pharma is doing great work and their product belongs on the market. . . but then so do countless other brands and options that currently have no hope of FDA and DEA approval.

They are certainly not the only company trying to make an end run on plant-based patents in the cannabis space so it will be interesting to continue to watch how the U.S. Patent Office decides to rule on future cases.

GW Pharma, with their exclusive blessing from the federal government, is in a wholly unique position to really do some good. Their public relations has suffered through the arduous process of gaining those approvals, but future efforts to help preserve the cannabis culture could go a long way toward regaining some respect from the grassroots, for whatever that’s worth to them.

Having this patent denied does not stop them from helping sick kids.
It stops them from stopping others from helping sick kids.

Thank you to the U.S. Patent Office for seeing it that way.

As the legalization movement gains momentum worldwide, cannabis-based research will only deepen our knowledge of the plant and its many benefits. Fueling that momentum in large part will be our rapidly improving technology as we refine breeding, cultivating, processing, and testing methods.

We’re seeing that now as science begins to accurately map the genome of cannabis and as exciting as that is, it also opens the door to the potential for smothering monopolies and corporate influence the likes of which our culture and this industry are just now starting to witness.

So we fight back and celebrate small victories.

Sign up today for the Friday Sesh Newsletter!

Your fresh harvest of grassroots cannabis news delivered every Friday alongside upcoming events, friendly updates, dope giveaways, homie hookups, rad sponsors, and more!

The email address is already subscribed.

Thanks for subscribing! See you at the Sesh!

One email every Friday Never spam, always dank
Newest Most Voted
Inline Feedbacks
View all comments
Wendy Goodwin
2 years ago

This aspect as new to me so will take time to get my head together. Spoke to GW this morning about the single isolate for Epidiolex, if it is just CBD it wouldn’t need a license in U.K. but it comes under “medicine” rules! I will not know GW as they have done a lot of research with epic Scientists such as Ethan Russo and I do declare the I am a Shareholder all £2000, just wish MP’s would declare their financial interests! Locally in East Yorkshire, England our local MP has invited Victoria Adkins to the area regarding hare… Read more »

Peter Reynolds
Peter Reynolds
2 years ago

Your journalism would be far more effective if it was accurate and you restrained the emotive hypebole.

Epidiolex is neither an isolate nor a tincture, it is a whole plant extract containing 98% CBD and 0.15% THC.

2 years ago
Reply to  Peter Reynolds

Please provide the link to the exact strain of plant that contains 98% CBD ?

2 years ago


this week in weed tv
2 years ago

Must be doing something right if the pharma trolls are here right 🙂 Well written, ACCURATE story. Here on Earth 1 – there is no full spectrum plant with 98% CBD, unless you had a blade of lawn grass with 98% added GMO CBD pharma isolate, that would be full spectrum also? 🙂 – The industry calls the CBD isolated pharma "API" now (cannabinoid active pharmaceutical ingredients) – So GMO vs full spectrum with added API – yum – GMO – how ? Per Hortpaharm here saying awhile ago, they created made to order genetically modified Cannabis for GW Pharma… Read more »

Vincent Capuano
Vincent Capuano
2 years ago

I invite you all to visit (and join) the "Cannabis IP" group in Linked-In, where we are discussing this patent and others. I’ve been a pharma patent attorney for 20+ years and I can’t believe what’s getting allowed at the PTO. You can also see my article there – "Can You Patent a Bong made Out of an Apple?" – on how cannabis and pharma have a lot in common when it comes to patents.

Related posts

Breeding the Culture: Oldtimer1 From the Counterculture to the Rise of Online Cannabis Community

Cannabis Cultivation

Breeding the Culture: Oldtimer1 From the Counterculture to the Rise of Online Cannabis Community

Oldtimer1 (Ot1) is a lifelong collector, grower, breeder, and preservationist of cannabis genetics from around the world. Since the 1960s Oldtimer1 has dedicated his life to collecting, preserving, and sharing knowledge about cannabis. As a breeder, he is best known for his work preserving unique traditional equatorial varieties.  Based in the UK, Oldtimer1 has been […]

Close menu
Beard Bros Media
Guest Contributions
Contribute an article
Contribute an event
Friday Sesh Newsletter
Beard Bros Pharms
Product Finder
Wholesale Distribution
Our Story
Your account
Manage cookie settings